Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07104799 · ClinicalTrials.gov registry record · Phase 1
Momelotinib During and After HCT in Myelofibrosis
A Phase 1 study of Myelofibrosis and Hematopoietic Cell Transplantation (HCT), sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT07104799 is a Phase 1 study of Myelofibrosis and Hematopoietic Cell Transplantation (HCT) that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 28 participants, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07104799, a Phase 1 study of Myelofibrosis and Hematopoietic Cell Transplantation (HCT), is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, open-label, phase I study to determine the safety and tolerability of momelotinib in patients with myelofibrosis during and after hematopoietic cell transplantation (HCT).
Conditions Studied
Interventions
- DRUG Momelotinib
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2030-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07104799
The ClinicalTrials.gov registry entry for NCT07104799 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (86% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which Momelotinib is the first listed.
NCT07104799 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07104799 about?
NCT07104799 is a clinical study titled "Momelotinib During and After HCT in Myelofibrosis". This is a single-center, open-label, phase I study to determine the safety and tolerability of momelotinib in patients with myelofibrosis during and after hematopoietic cell transplantation (HCT).
What is the current status of trial NCT07104799?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2026-01-01. Estimated completion is 2030-01.
What conditions does trial NCT07104799 study?
This clinical trial studies the following conditions: Myelofibrosis, Hematopoietic Cell Transplantation (HCT).
What interventions are being tested in trial NCT07104799?
The interventions under investigation include: Momelotinib (DRUG).
Who is sponsoring clinical trial NCT07104799?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07104799 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RECRUITING · Phase 1
-
A Safety and Tolerability Study of Jaktinib
RECRUITING · Phase 1
Explore more on PlainTrial
Myelofibrosis
All registered trials for this condition
Hematopoietic Cell Transplantation (HCT)
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.